Physician profile
Marlene Kolb
NPI 1164129391
$2,343.97
in general payments reported to CMS, 2019-2025
23 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what 97% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $427 · 2024: $561 · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,107 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.04 |
| Education | $236.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $558.01 | 2024-2025 | Veozah |
| Shield Therapeutics INC | $257.00 | 2023-2025 | Accrufer |
| Mayne Pharma Commercial LLC | $224.16 | 2023-2025 | |
| Abbvie INC. | $194.86 | 2023-2025 | |
| Sage Therapeutics, LLC | $184.07 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $137.36 | 2024-2025 | Injectafer |
| Exeltis, USA INC. | $125.08 | 2023-2025 | Slynd |
| Myriad Women'S Health, INC. | $102.53 | 2023 | Myrisk |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.15 | 2024-2025 | Xifaxan |
| Aspira Women'S Health INC | $59.18 | 2024 | Ova1 |
| Sumitomo Pharma America, INC. | $58.32 | 2023-2025 | Myfembree |
| Evofem Biosciences, INC. | $54.58 | 2023-2025 | Phexxi, Solosec, Phexx |
| Organon LLC | $53.31 | 2023 | Nexplanon |
| Supernus Pharmaceuticals, INC. | $48.34 | 2025 | Qelbree |
| Coopersurgical, INC. | $43.29 | 2023-2024 | Paragard T 380a, Paragard T 380a |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $32.81 | 2025 | Perclot |
| Hologic Sales and Service, LLC | $30.38 | 2024 | Aptima |
| Dexcom, INC. | $28.81 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $17.59 | 2023 | Prolia, Evenity |
| Exact Sciences Corporation | $17.47 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $17.23 | 2024 | |
| Millicent US INC | $16.74 | 2024 | Femring, Intrarosa |
| Medline Industries LP | $16.70 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlene Kolb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.